These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 10607684

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.
    Lajoie G, Kumar S, Min KW, Silva FG.
    Am J Surg Pathol; 1995 Sep; 19(9):1021-8. PubMed ID: 7661275
    [Abstract] [Full Text] [Related]

  • 6. Idiopathic multicentric Castleman's disease: a systematic literature review.
    Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC.
    Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T, Sumiyoshi R, Kawakami A, Yoshizaki K.
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Castleman's disease: from basic mechanisms to molecular therapeutics.
    El-Osta HE, Kurzrock R.
    Oncologist; 2011 Mar; 16(4):497-511. PubMed ID: 21441298
    [Abstract] [Full Text] [Related]

  • 13. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.
    Ikeda S, Chisuwa H, Kawasaki S, Ozawa J, Hoshii Y, Yokota T, Aoi T.
    J Clin Pathol; 1997 Nov; 50(11):965-7. PubMed ID: 9462253
    [Abstract] [Full Text] [Related]

  • 14. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
    Kinney MC, Hummell DS, Villiger PM, Hourigan A, Rollins-Smith L, Glick AD, Lawton AR.
    J Clin Immunol; 1994 Nov; 14(6):382-90. PubMed ID: 7883866
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Transitional type of Castleman's disease manifested as the POEMS syndrome].
    Tomić I, Plavec G, Tasić O, Ristanović A, Cvijanović V.
    Vojnosanit Pregl; 2004 Nov; 61(4):439-44. PubMed ID: 15552541
    [Abstract] [Full Text] [Related]

  • 17. Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.
    Chabchoub I, Salah RB, Kallel R, Snoussi M, Frikha F, Marzouk S, Boudawara TS, Bahloul Z.
    Rom J Intern Med; 2024 Mar 01; 62(1):20-32. PubMed ID: 37948573
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.